150 related articles for article (PubMed ID: 16702895)
1. To what extent do the PANSS and CGI-S overlap?
Rabinowitz J; Mehnert A; Eerdekens M
J Clin Psychopharmacol; 2006 Jun; 26(3):303-7. PubMed ID: 16702895
[TBL] [Abstract][Full Text] [Related]
2. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
Gharabawi G; Bossie C; Turkoz I; Kujawa M; Mahmoud R; Simpson G
J Nerv Ment Dis; 2007 Dec; 195(12):976-82. PubMed ID: 18091190
[TBL] [Abstract][Full Text] [Related]
3. Revisiting the 5 dimensions of the Positive and Negative Syndrome Scale.
Levine SZ; Rabinowitz J
J Clin Psychopharmacol; 2007 Oct; 27(5):431-6. PubMed ID: 17873671
[TBL] [Abstract][Full Text] [Related]
4. Concordance between measures of functioning, symptoms, and change: examining the GAF, CGI-S, CGI-C, and PANSS.
Rabinowitz J; Levine S; Martinez G
J Clin Psychopharmacol; 2010 Aug; 30(4):478-80. PubMed ID: 20631575
[No Abstract] [Full Text] [Related]
5. N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial.
Berk M; Copolov D; Dean O; Lu K; Jeavons S; Schapkaitz I; Anderson-Hunt M; Judd F; Katz F; Katz P; Ording-Jespersen S; Little J; Conus P; Cuenod M; Do KQ; Bush AI
Biol Psychiatry; 2008 Sep; 64(5):361-8. PubMed ID: 18436195
[TBL] [Abstract][Full Text] [Related]
6. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
[TBL] [Abstract][Full Text] [Related]
7. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
8. Patient-based and clinician-based support for the remission criteria in schizophrenia.
Docherty JP; Bossie CA; Lachaux B; Bouhours P; Zhu Y; Lasser R; Gharabawi GM
Int Clin Psychopharmacol; 2007 Jan; 22(1):51-5. PubMed ID: 17159460
[TBL] [Abstract][Full Text] [Related]
9. Long-acting risperidone improves negative symptoms in stable psychotic patients.
Curtis VA; Katsafouros K; Möller HJ; Medori R; Sacchetti E
J Psychopharmacol; 2008 May; 22(3):254-61. PubMed ID: 18308804
[TBL] [Abstract][Full Text] [Related]
10. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI.
Levine SZ; Rabinowitz J; Engel R; Etschel E; Leucht S
Schizophr Res; 2008 Jan; 98(1-3):318-22. PubMed ID: 17949948
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
Zink M; Kuwilsky A; Krumm B; Dressing H
J Psychopharmacol; 2009 May; 23(3):305-14. PubMed ID: 18562423
[TBL] [Abstract][Full Text] [Related]
12. Testosterone in first-episode schizophrenia.
Cesková E; Prikryl R; Kaspárek T
Neuro Endocrinol Lett; 2007 Dec; 28(6):811-4. PubMed ID: 18063925
[TBL] [Abstract][Full Text] [Related]
13. The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials.
Kinon BJ; Ascher-Svanum H; Adams DH; Chen L
J Clin Psychopharmacol; 2008 Oct; 28(5):544-9. PubMed ID: 18794651
[TBL] [Abstract][Full Text] [Related]
14. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
[TBL] [Abstract][Full Text] [Related]
15. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584
[TBL] [Abstract][Full Text] [Related]
16. Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia.
Nasrallah H; Morosini P; Gagnon DD
Psychiatry Res; 2008 Nov; 161(2):213-24. PubMed ID: 18848731
[TBL] [Abstract][Full Text] [Related]
17. Brief PANSS to assess and monitor the overall severity of schizophrenia.
Yamamoto N; Inada T; Shimodera S; Morokuma I; Furukawa TA
Psychiatry Clin Neurosci; 2010 Jun; 64(3):262-7. PubMed ID: 20602726
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Ratner Y; Gibel A; Yorkov V; Ritsner MS
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
[TBL] [Abstract][Full Text] [Related]
19. Dimensions of psychosis in patients with bipolar mania as measured by the positive and negative syndrome scale.
Lindenmayer JP; Bossie CA; Kujawa M; Zhu Y; Canuso CM
Psychopathology; 2008; 41(4):264-70. PubMed ID: 18441528
[TBL] [Abstract][Full Text] [Related]
20. Psychotic symptoms in patients with bipolar mania.
Canuso CM; Bossie CA; Zhu Y; Youssef E; Dunner DL
J Affect Disord; 2008 Dec; 111(2-3):164-9. PubMed ID: 18378001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
